Matthew Ku Selected Research

Matthew Ku Research Topics

7	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 02/2022 - 01/2021
5	Neoplasms (Cancer) 01/2022 - 01/2020
4	Lymphoma (Lymphomas) 01/2021 - 01/2017
2	Hematologic Neoplasms (Hematological Malignancy) 10/2022 - 03/2015
2	COVID-19 01/2021 - 01/2020
1	Hypoalbuminemia 10/2022
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022
1	Chemotherapy-Related Cognitive Impairment 10/2021
1	Infections 01/2021
1	Hodgkin Disease (Hodgkin's Disease) 12/2020
1	Pathologic Complete Response 12/2020
1	Otitis Media 11/2020
1	Splenomegaly 01/2019
1	Polycythemia (Erythrocytosis) 01/2019
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2017
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 03/2014
1	Pure Red-Cell Aplasia 03/2014
1	Autism Spectrum Disorder 01/2014
1	Neurodevelopmental Disorders 01/2014
1	Myocardial Infarction 01/2011
1	Aortic Dissection 01/2011

5	selinexorIBA 02/2022 - 01/2021
3	Methotrexate (Mexate)FDA LinkGeneric 10/2022 - 01/2020
2	Drug CombinationsIBA 11/2020 - 01/2017
1	tafasitamabIBA 01/2022
1	Lenalidomide (CC 5013)FDA Link 01/2022
1	Alkylating AgentsIBA 01/2022
1	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Ciprofloxacin (Cipro)FDA LinkGeneric 11/2020
1	Dexamethasone (Maxidex)FDA LinkGeneric 11/2020
1	HydrogelsIBA 11/2020
1	Protein Tyrosine PhosphatasesIBA 01/2019
1	Phosphotransferases (Kinase)IBA 01/2019
1	Surface Antigens (Surface Antigen)IBA 01/2017
1	Bispecific AntibodiesIBA 01/2017
1	Rituximab (Mabthera)FDA Link 01/2017
1	src-Family KinasesIBA 03/2015
1	Biomarkers (Surrogate Marker)IBA 01/2014
1	LumicanIBA 01/2011
1	N 30IBA 01/2011

11	Therapeutics 01/2022 - 03/2015
2	Stem Cell Transplantation 10/2021 - 01/2021
2	Drug Therapy (Chemotherapy) 12/2020 - 03/2014
1	Activities of Daily Living (ADL) 10/2021
1	Cognitive Training 10/2021
1	Radiotherapy 01/2021
1	Middle Ear Ventilation (Tympanostomy) 11/2020